Lv523
1220 积分 2024-04-01 加入
Protein degraders push into novel target space
1天前
已完结
Molecular mechanism of IgE-mediated FcεRI activation
14天前
已完结
From TCR fundamental research to innovative chimeric antigen receptor design
17天前
已完结
The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development
18天前
已完结
Therapeutic potential of cis-targeting bispecific antibodies
30天前
已完结
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy
1个月前
已完结
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
1个月前
已完结
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
1个月前
已完结
Cancer therapy with antibodies
1个月前
已完结
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy
1个月前
已完结
皖公网安备34019202002308
